Applications of AI in healthcare, including medical diagnostics, drug discovery, patient care solutions, and biotechnology research.
Mount Sinai Health System will implement Clarium’s AI-powered computer vision technology across its hospitals to automate surgical supply tracking and reduce waste, according to a press release.
Converge Bio has secured a $2.5 million grant from the Gates Foundation to expand its AI gene discovery platform from pharmaceuticals to crop genomics, aiming to improve agricultural resilience and accelerate crop breeding cycles.
Tissue Dynamics and Galmed Pharmaceuticals have discovered a previously unknown metabolic mechanism involved in cardiac fibrosis using human cardiac organoid models, showing that a combination of Aramchol Meglumine and a PPARα agonist can significantly reduce fibrotic burden.
The U.S. Food and Drug Administration has cleared Clarius Mobile Health's Ejection Fraction AI tool, which automates cardiac ultrasound analysis to measure heart pumping efficiency in real time within the Clarius App.
Genomics has launched Mystra AI, a conversational platform that leverages the world's largest human genetics database to support drug target discovery and validation, offering researchers access to genetic insights through plain language queries.
Compal Electronics showcased its POLYMEDX Physical AI platform at COMPUTEX 2026, highlighting expanded collaboration with NVIDIA to accelerate smart hospital operations through robotics, AI orchestration, and digital twin technologies.
Kedrion Biopharma and InstaLILY will co-host the Rare Connections: Healthcare AI Innovation Summit on June 3 during NY Tech Week, bringing together leaders from pharma, technology, and research to discuss the practical use of AI in healthcare.
AssureCare has launched NutraVance, an AI-enabled platform that integrates nutrition management directly into healthcare workflows, supporting Food as Medicine programs with tools for assessment, care planning, engagement, and reimbursement.
Conscientia Health has launched a clinician supervised AI platform designed to support mental health providers with tools for patient matching, clinical decision support, and predictive insights.
3billion has introduced 3B-NEO, a genomic newborn screening service analyzing 595 genes linked to actionable childhood disorders, with results delivered in about two weeks.
GRAIL presented full results from the NHS-Galleri trial at the 2026 ASCO Annual Meeting, showing a reduction in Stage IV cancer diagnoses and increased detection rates when the Galleri test was added to standard screening.
Nucs AI has announced a collaboration with AstraZeneca to develop AI models that predict patient response to PSMA-targeted radioconjugate therapies for metastatic prostate cancer.
Holmusk has expanded its NeuroBlu platform to include data from more than 46 million de-identified patients, adding new neurological health systems, structured biomarker information, and validated outcomes across multiple disease areas.
South Korea-based SKIA has received FDA 510(k) clearance for its SKIA HEAD augmented reality surgical guidance system, paving the way for a U.S. launch through a partnership with Structure.
Cognizant has introduced AI agent access to its TriZetto Unify healthcare platform, starting with Electronic Prior Authorization through a new headless API model designed for governed and auditable automation.
World Health Expo Miami will return to the Miami Beach Convention Center from June 17 to 19, 2026, showcasing AI, robotics, and digital health innovations across the healthcare industry.
Causaly has launched Scientific Workflows, a new feature in its AI platform that codifies expert scientific methods into automated, multi-agent workflows for biopharma R&D teams.
Labcorp has partnered with the Alliance for Clinical Trials in Oncology to support a national study evaluating ways to expand genetic testing for colorectal cancer patients and their families, with support from the National Cancer Institute.
Alaw Therapeutics has begun dosing patients in a Phase 1a/b trial for its CDK2 inhibitor AL-605 and named AL-433 as a new CDK4 drug candidate, with clinical entry planned for late 2026.
Sino Biological announced that its cell-free protein synthesis workflow was used by Tencent AI for Life Sciences Lab in a Nature Communications study to validate AI-designed proteins with enhanced activity, stability, and multifunctionality.
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
